Longitudinal Developmental Profile of Newborns and Toddlers Treated for Spinal Muscular Atrophy

Overview

Journal Ther Adv Neurol Disord

Specialty Neurology

Date 2023 Feb 27

PMID 36846472

Authors

Magali Ngawa

Fabian Dal Farra

Andrei-Dan Marinescu

Laurent Servais

Affiliations

Soon will be listed here.

Abstract

Background: Spinal muscular atrophy (SMA) results from a loss-of-function mutation in the gene. SMA patients suffer progressive motor disability, although no intellectual impairments have been described. Three drugs have been recently approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These drugs result in longer life expectancy for SMA type 1 (SMA1) patients.

Objective: The objective of the study was to assess longitudinally the psychomotor development of patients with SMA1 treated after the symptom onset and of patients treated presymptomatically.

Design: Longitudinal, monocentric, noninterventional, prospective study.

Methods: Our study included 11 SMA1 patients and seven presymptomatic SMA patients. The SMA1 patients were treated with an approved drug beginning after onset of symptoms; treatment for the presymptomatic patients was begun before symptom onset. They were longitudinally evaluated between September 2018 and January 2022 using the Bayley Scales of Infant and Toddler Development™ - Third Edition.

Results: At each time point, all patients treated presymptomatically scored above those treated postsymptomatically on the motor scale. The cognitive scores of six of the seven patients treated presymptomatically were average; one patient was in the low average range. In the 11 postsymptomatically treated patients, four scored either in the low average or the abnormal range on the cognitive scale, but a positive trend was observed during the follow-up.

Conclusion: A significant proportion of patients treated postsymptomatically scored below average on cognitive and communicative scales, with most significant concerns raised about the age of 1 year. Our study indicates that intellectual development should be considered as an important outcome in treated SMA1 patients. Cognitive and communicative evaluations should be performed as part of standard of care, and guidance should be provided to parents for optimal stimulation.

Citing Articles

Home mechanical ventilation in children: evolving indications in an era of new treatment options.

Tan H, Chawla J Eur Respir Rev. 2024; 33(174).

PMID: 39694585 PMC: 11653194. DOI: 10.1183/16000617.0154-2024.

Brain magnetic resonance imaging of patients with spinal muscular atrophy type 2 and 3.

Stam M, Tan H, Schmidt R, van den Heuvel M, van den Berg L, Wadman R Neuroimage Clin. 2024; 44:103708.

PMID: 39577334 PMC: 11617753. DOI: 10.1016/j.nicl.2024.103708.

Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients.

Mackels L, Mariot V, Buscemi L, Servais L, Dumonceaux J Int J Mol Sci. 2024; 25(16).

PMID: 39201450 PMC: 11354404. DOI: 10.3390/ijms25168763.

Systematic Review of Presymptomatic Treatment for Spinal Muscular Atrophy.

Cooper K, Nalbant G, Sutton A, Harnan S, Thokala P, Chilcott J Int J Neonatal Screen. 2024; 10(3).

PMID: 39189228 PMC: 11348213. DOI: 10.3390/ijns10030056.

Cognition and communication in patients with spinal muscular atrophy: A systematic review.

Akodad S, De Smedt D, Baijot S, Stevens H, Deconinck N Heliyon. 2024; 10(13):e33677.

PMID: 39040255 PMC: 11261103. DOI: 10.1016/j.heliyon.2024.e33677.

References

Baranello G, Darras B, Day J, Deconinck N, Klein A, Masson R . Risdiplam in Type 1 Spinal Muscular Atrophy. N Engl J Med. 2021; 384(10):915-923. DOI: 10.1056/NEJMoa2009965. View

Masson R, Brusa C, Scoto M, Baranello G . Brain, cognition, and language development in spinal muscular atrophy type 1: a scoping review. Dev Med Child Neurol. 2021; 63(5):527-536. DOI: 10.1111/dmcn.14798. View

Ebbink B, Poelman E, Aarsen F, Plug I, Regal L, Muentjes C . Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain. Dev Med Child Neurol. 2018; 60(6):579-586. DOI: 10.1111/dmcn.13740. View

Dangouloff T, Vrscaj E, Servais L, Osredkar D . Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go. Neuromuscul Disord. 2021; 31(6):574-582. DOI: 10.1016/j.nmd.2021.03.007. View

Dangouloff T, Hiligsmann M, Deconinck N, DAmico A, Seferian A, Boemer F . Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening. Dev Med Child Neurol. 2022; 65(1):67-77. DOI: 10.1111/dmcn.15286. View

Yohannan M, Patel P, Kolawole T, Malabarey T, Mahdi A . Brain atrophy in Werdnig-Hoffmann disease. Acta Neurol Scand. 1991; 84(5):426-8. DOI: 10.1111/j.1600-0404.1991.tb04982.x. View

Laufersweiler-Plass C, Rudnik-Schoneborn S, Zerres K, Backes M, Lehmkuhl G, von Gontard A . Behavioural problems in children and adolescents with spinal muscular atrophy and their siblings. Dev Med Child Neurol. 2003; 45(1):44-9. View

Aragon-Gawinska K, Seferian A, Daron A, Gargaun E, Vuillerot C, Cances C . Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study. Neurology. 2018; 91(14):e1312-e1318. DOI: 10.1212/WNL.0000000000006281. View

Zappa G, LoMauro A, Baranello G, Cavallo E, Corti P, Mastella C . Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1. J Neurodev Disord. 2021; 13(1):9. PMC: 7856807. DOI: 10.1186/s11689-021-09355-4. View

10.

Zimmerman F, Christakis D, Meltzoff A . Associations between media viewing and language development in children under age 2 years. J Pediatr. 2007; 151(4):364-8. DOI: 10.1016/j.jpeds.2007.04.071. View

11.

Lenzoni S, Semenza C, Calligaro D, Turcano P, Caumo L, Pegoraro E . Cognitive profiles and clinical factors in type III spinal muscular atrophy: a preliminary study. Neuromuscul Disord. 2022; 32(8):672-677. DOI: 10.1016/j.nmd.2022.05.005. View

12.

Harding B, Kariya S, Monani U, Chung W, Benton M, Yum S . Spectrum of neuropathophysiology in spinal muscular atrophy type I. J Neuropathol Exp Neurol. 2014; 74(1):15-24. PMC: 4350580. DOI: 10.1097/NEN.0000000000000144. View

13.

von Gontard A, Zerres K, Backes M, Laufersweiler-Plass C, Wendland C, Melchers P . Intelligence and cognitive function in children and adolescents with spinal muscular atrophy. Neuromuscul Disord. 2001; 12(2):130-6. DOI: 10.1016/s0960-8966(01)00274-7. View

14.

Dangouloff T, Burghes A, Tizzano E, Servais L . 244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands. Neuromuscul Disord. 2019; 30(1):93-103. DOI: 10.1016/j.nmd.2019.11.002. View

15.

Strauss K, Farrar M, Muntoni F, Saito K, Mendell J, Servais L . Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022; 28(7):1381-1389. PMC: 9205281. DOI: 10.1038/s41591-022-01866-4. View

16.

Fluss J, Lidzba K . Cognitive and academic profiles in children with cerebral palsy: A narrative review. Ann Phys Rehabil Med. 2020; 63(5):447-456. DOI: 10.1016/j.rehab.2020.01.005. View

17.

Dangouloff T, Servais L . Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives. Ther Clin Risk Manag. 2019; 15:1153-1161. PMC: 6778729. DOI: 10.2147/TCRM.S172291. View

18.

Strauss K, Farrar M, Muntoni F, Saito K, Mendell J, Servais L . Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022; 28(7):1390-1397. PMC: 9205287. DOI: 10.1038/s41591-022-01867-3. View

19.

Verhaart I, Robertson A, Wilson I, Aartsma-Rus A, Cameron S, Jones C . Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017; 12(1):124. PMC: 5496354. DOI: 10.1186/s13023-017-0671-8. View

20.

De Vivo D, Bertini E, Swoboda K, Hwu W, Crawford T, Finkel R . Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019; 29(11):842-856. PMC: 7127286. DOI: 10.1016/j.nmd.2019.09.007. View